Cargando…

Obese children with fatty liver: Between reality and disease mongering

Following the current epidemic of obesity, the worldwide prevalence of nonalcoholic fatty liver disease (NAFLD) has increased with potential serious health implications. While it is established that in adults NAFLD can progress to end-stage liver disease in many cases, the risk of progression during...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ranucci, Giusy, Spagnuolo, Maria Immacolata, Iorio, Raffaele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2017
Materias:	Minireviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743498/ https://www.ncbi.nlm.nih.gov/pubmed/29307987 http://dx.doi.org/10.3748/wjg.v23.i47.8277

Ejemplares similares

Zinc monotherapy is effective in Wilson’s disease patients with mild liver disease diagnosed in childhood: a retrospective study
por: Ranucci, Giusy, et al.
Publicado: (2014)

Confessions of a Disease Monger
por: Phelps, James
Publicado: (2006)

The Punishment of Abortion-Mongers
Publicado: (1887)

Fatty liver without a large “belly”: Magnified review of non-alcoholic fatty liver disease in non-obese patients
por: Yousef, Mohamad H, et al.
Publicado: (2017)

Disease Mongering: One of the Hidden Consequences
por: Gillman, Kenneth
Publicado: (2006)

Coronavirus disease 2019 severity in obesity: Metabolic dysfunction-associated fatty liver disease in the spotlight
por: Vasques-Monteiro, Isabela Macedo Lopes, et al.
Publicado: (2021)

Associations between nonalcoholic fatty liver disease and ischemic stroke
por: Alkagiet, Stelina, et al.
Publicado: (2018)

Redefining non-alcoholic fatty liver disease to metabolic associated fatty liver disease: Is this plausible?
por: Devi, Jalpa, et al.
Publicado: (2022)

Relationship between non-alcoholic fatty liver disease and coronary heart disease
por: Arslan, Ugur, et al.
Publicado: (2020)

Combating Disease Mongering: Daunting but Nonetheless Essential
por: Heath, Iona
Publicado: (2006)

Questionable Advertising of Psychotropic Medications and Disease Mongering
por: Lacasse, Jeffrey R, et al.
Publicado: (2006)

The Newest Mania: Seeing Disease Mongering Everywhere
por: Ghaemi, S. Nassir
Publicado: (2006)

Non-alcoholic fatty liver disease
por: Neuschwander-Tetri, Brent A.
Publicado: (2017)

Growing challenge of post-liver transplantation non-alcoholic fatty liver disease
por: Kalogirou, Maria Styliani, et al.
Publicado: (2022)

Mediterranean diet and nonalcoholic fatty liver disease
por: Anania, Caterina, et al.
Publicado: (2018)

Fatty liver and celiac disease: Why worry?
por: Narciso-Schiavon, Janaina Luz, et al.
Publicado: (2023)

Gossip mongers push for national networks
por: Pearson, Helen
Publicado: (2005)

The Fight against Disease Mongering: Generating Knowledge for Action
por: Moynihan, Ray, et al.
Publicado: (2006)

Disease Mongering Is Now Part of the Global Health Debate
por: Moynihan, Ray, et al.
Publicado: (2008)

Non-alcoholic fatty liver disease and cardiovascular risk
por: Patil, Rashmee, et al.
Publicado: (2017)

Diabetes and fatty liver: Involvement of incretin and its benefit for fatty liver management
por: Wibawa, I Dewa Nyoman, et al.
Publicado: (2023)

COVID-19 and pediatric fatty liver disease: Is there interplay?
por: Di Sessa, Anna, et al.
Publicado: (2021)

Sex dimorphism and metabolic profiles in management of metabolic-associated fatty liver disease
por: Martin-Grau, Maria, et al.
Publicado: (2023)

Shifting perspectives – interplay between non-alcoholic fatty liver disease and insulin resistance in lean individuals
por: Bilic-Curcic, Ines, et al.
Publicado: (2021)

Metabolic associated fatty liver disease: Addressing a new era in liver transplantation
por: Gill, Madeleine G, et al.
Publicado: (2020)

Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma
por: Said, Adnan, et al.
Publicado: (2017)

Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease
por: Wong, Carrie R, et al.
Publicado: (2016)

Multiomics biomarkers for the prediction of nonalcoholic fatty liver disease severity
por: Pirola, Carlos J, et al.
Publicado: (2018)

Advances in paediatric nonalcoholic fatty liver disease: Role of lipidomics
por: Di Sessa, Anna, et al.
Publicado: (2021)

Management of metabolic-associated fatty liver disease: The diabetology perspective
por: Jeeyavudeen, Mohammad Sadiq, et al.
Publicado: (2023)

Emerging role of engineered exosomes in nonalcoholic fatty liver disease
por: Ding, Jian, et al.
Publicado: (2023)

De novo and recurrence of metabolic dysfunction-associated fatty liver disease after liver transplantation
por: Han, Ma Ai Thanda, et al.
Publicado: (2021)

Liver tumors in children with chronic liver diseases
por: Sintusek, Palittiya, et al.
Publicado: (2021)

Racial differences in prevalence and severity of non-alcoholic fatty liver disease
por: Bonacini, Maurizio, et al.
Publicado: (2021)

Hepatocellular carcinoma in nonalcoholic fatty liver disease: A growing challenge
por: Mattos, Ângelo Z, et al.
Publicado: (2021)

Nonalcoholic fatty liver disease and COVID-19: An epidemic that begets pandemic
por: Ahmed, Musaab, et al.
Publicado: (2021)

Therapies for non-alcoholic fatty liver disease: A 2022 update
por: Shen, Katie, et al.
Publicado: (2022)

Implications of metabolic dysfunction associated fatty liver disease in COVID-19
por: Chakraborty, Raja, et al.
Publicado: (2023)

Fairness Creams in South Asia—A Case of Disease Mongering?
por: Shankar, P. Ravi, et al.
Publicado: (2006)

Non-alcoholic fatty liver disease and COVID-19: Harmless companions or disease intensifier?
por: Dietrich, Christoph G, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rregj0glhda1n7q2jo622ni0uo